Our group has demonstrated that a long-acting muscarinic receptor antagonist, which is used for asthma, suppresses basophil-derived IL-4 production and subsequently regulates ILC2 activation to ameliorate airway eosinophilic inflammation in a murine model [44]. Here, IL4 is linked to asthma.